DBL Vinblastine Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Vinblastine sulfate

Indications/Uses

Hodgkin's disease (stages 3 & 4), advanced testicular carcinoma. Palliative treatment of lymphocytic & histiocytic lymphoma, advanced stages of mycosis fungoides, Kaposi's sarcoma, histiocytosis X. Choriocarcinoma resistant to other chemotherapeutic agents & breast carcinoma unresponsive to appropriate endocrine surgery & hormonal therapy.

Click to view DBL Vinblastine detailed prescribing information

Dosage/Direction for Use

Adult 1st dose: 3.7 mg/m² once every 7 days. 2nd dose: 5.5 mg/m² once every 7 days. 3rd dose: 7.4 mg/m² once every 7 days. 4th dose: 9.25 mg/m² once every 7 days. 5th dose: 11.1 mg/m² once every 7 days. Increased dosage may be continued but must not exceed 18.5 mg/m² once every 7 days. Childn 1st dose: 2.5 mg/m² once every 7 days. 2nd dose: 3.75 mg/m² once every 7 days. 3rd dose: 5 mg/m² once every 7 days. 4th dose: 6.25 mg/m² once every 7 days. 5th dose: 7.5 mg/m² once every 7 days. Increased dosage may be continued but must not exceed 12.5 mg/m² once every 7 days. Discontinue dosage increase for adult & childn after dose which reduces white cell count to approx 3 x 10⁹/L (3,000/mm³).

Click to view DBL Vinblastine detailed prescribing information

Overdosage

View DBL Vinblastine overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity. Leukopenia. Not be used in presence of bacterial infection.

Click to view DBL Vinblastine detailed prescribing information

Special Precautions

Not to be given IM, SC or intrathecally. Avoid IV inj into extremities. Severe local reaction on extravasation. Myelosuppression; malignant-cell bone marrow infiltration; impaired bone marrow from prior therapy w/ radiation or other oncolytic drugs. Monitor carefully for infection until white cell count & granulocyte has returned to normal levels if leucopenia w/ <2,000 WBC/mm³; granulocytopenia w/ <1,000 granulocytes/mm³ occurs. Avoid eye contamination & infiltration of SC tissues. High-dose & long-term use. May affect ability to drive & use machines. Hepatic impairment. May affect male fertility. Women of childbearing potential should use effective contraception during & for at least 6 mth after last dose. Pregnancy & lactation. Avoid use in elderly w/ cachexia or ulcerated skin surface areas.

Click to view DBL Vinblastine detailed prescribing information

Use In Pregnancy & Lactation

Click to view DBL Vinblastine detailed prescribing information

Adverse Reactions

Leucopenia.

Click to view DBL Vinblastine detailed prescribing information

Drug Interactions

Delay inj if given in conjunction w/ RT through liver ports. Fatal acute resp distress or failure w/ mitomycin. Reduced blood levels & increased seizure activity of phenytoin. Increased plasma conc & neutropenia severity w/ cisplatin. Declined GFR w/ bleomycin, cisplatin. Increased toxicity w/ erythromycin. Reduced anticonvulsants serum levels. Amenorrhea in combination w/ other drugs. Leukaemia following RT & in combination w/ alkylating agents. Earlier onset &/or increased side effects severity w/ CYP3A inhibitors. Precipitation w/ furosemide.

Click to view DBL Vinblastine detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view DBL Vinblastine detailed prescribing information

Storage

View DBL Vinblastine storage conditions for details to ensure optimal shelf-life.

Description

View DBL Vinblastine description for details of the chemical structure and excipients (inactive components).

Action

View DBL Vinblastine mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01CA01 - vinblastine ; Belongs to the class of plant alkaloids and other natural products, vinca alkaloids and analogues. Used in the treatment of cancer.

Regulatory Classification

Presentation/Packing

Form

DBL Vinblastine soln for inj 10 mg/10 mL

Packing/Price

5 × 1's

DBL Vinblastine

vinblastine

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma